MediGene divests oncolytic HSV program

MediGene AG (Xetra:MDG) divested its oncolytic herpes simplex virus (HSV) program to Catherex Inc. (Philadelphia, Pa.) in exchange for a 40% stake in the new company. The program includes NV1020 and G207, which are in Phase I/II testing to treat liver metastases of colon cancer and glioma, respectively. Catherex plans to start multiple clinical programs next year. MediGene is eligible for undisclosed stock options or a one-time payment, if Catherex further develops the NV1020 program. MediGene also will appoint two Catherex board members. ...